PCT

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:
C12N 1/19, 15/81, C12P 21/02 // C12N 9/58

(11) International Publication Number: WO 96/29391
(43) International Publication Date: 26 September 1996 (26.09.96)

(21) International Application Number: PCT/DK96/00111
(22) International Filing Date: 20 March 1996 (20.03.96)
(30) Priority Data:
0284/95 20 March 1995 (20.03.95) DK

(71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK], Novo Allé, DK-2880 Bagsværd (DK).

(72) Inventor: and
(75) Inventor/Applicant (for US only): LEHMBECK, Jan [DK/DK], Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK).

(74) Common Representative: NOVO NORDISK A/S; Corporate Patents, Novo Allé, DK-2880 Bagsværd (DK).


Published
With international search report.

(54) Title: HOST CELL EXPRESSING REDUCED LEVELS OF A METALLOPROTEASE AND METHODS USING THE HOST CELL IN PROTEIN PRODUCTION

(57) Abstract

The present invention relates to novel host cells and to methods of producing proteins. More specifically the invention relates to a host cell useful for the expression of heterologous proteins, which host cell has been genetically modified in order to express significantly reduced levels of a metalloprotease. Moreover the invention relates to a method of producing a heterologous protein, which method comprises cultivating the host cell in a suitable growth medium, followed by recovery of the desired protein.
FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| AM | Armenia          | GB | United Kingdom |
| AT | Austria          | GE | Georgia        |
| AU | Australia        | GN | Guinea         |
| BB | Barbados         | GR | Greece         |
| BE | Belgium          | HU | Hungary        |
| BF | Burkina Faso     | IE | Ireland        |
| BG | Bulgaria         | IT | Italy          |
| BJ | Benin            | JP | Japan          |
| BR | Brazil           | KE | Kenya          |
| BY | Belarus          | KG | Kyrgyzstan     |
| CA | Canada           | KP | Democratic People’s Republic of Korea |
| CF | Central African Republic | KR | Republic of Korea |
| CG | Congo            | KZ | Kazakhstan     |
| CH | Switzerland      | LI | Liechtenstein  |
| CI | Côte d’Ivoire    | LK | Sri Lanka      |
| CM | Cameroon         | LR | Liberia        |
| CN | China            | LT | Lithuania      |
| CS | Czechoslovakia   | LU | Luxembourg     |
| CZ | Czech Republic   | LV | Latvia         |
| DE | Germany          | MC | Monaco         |
| DK | Denmark          | MD | Republic of Moldova |
| EE | Estonia          | MG | Madagascar     |
| ES | Spain            | ML | Mali           |
| FI | Finland          | MN | Mongolia       |
| FR | France           | MR | Mauritania     |
| GA | Gabon            | MW | Malawi         |
| MX | Mexico           | NE | Niger          |
| NL | Netherlands      | NO | Norway         |
| NZ | New Zealand      | PL | Poland         |
| PT | Portugal         | RO | Romania        |
| RU | Russian Federation | SD | Sudan           |
| SE | Sweden           | SG | Singapore      |
| SI | Slovenia         | SK | Slovakia       |
| SN | Senegal          | SZ | Swaziland      |
| TD | Chad             | TG | Togo           |
| TJ | Tajikistan       | TT | Trinidad and Tobago |
| UA | Ukraine          | UG | Uganda         |
| US | United States of America | UZ | Uzbekistan     |
| VN | Viet Nam         |
HOST CELL EXPRESSING REDUCED LEVELS OF A METALLOPROTEASE AND METHODS USING THE HOST CELL IN PROTEIN PRODUCTION

TECHNICAL FIELD

The present invention relates to novel host cells and to methods of producing proteins. More specifically the invention relates to a host cell useful for the expression of heterologous proteins, which host cell has been genetically modified in order to express significantly reduced levels of a metalloprotease. Moreover the invention relates to a method of producing a heterologous protein, which method comprises cultivating the host cell in a suitable growth medium, followed by recovery of the desired protein.

BACKGROUND ART

The use of recombinant host cells in the expression of heterologous proteins has in recent years greatly simplified the production of large quantities of commercially valuable proteins, which otherwise are obtainable only by purification from their native sources. Currently, there is a varied selection of expression systems from which to choose for the production of any given protein, including eubacterial and eucaryotic hosts. The selection of an appropriate expression system often not only depends on the ability of the host cell to produce adequate yields of the protein in an active state, but also to a large extent may be governed by the intended end use of the protein.

One problem frequently encountered is the high level of proteolytic enzymes produced by a given host cell or in the culture medium. It has been suggested that one could provide host organism deprived of the ability of producing specific proteolytic compounds. For example, International Patent Application WO 90/00192 describes filamentous fungal hosts incapable of excreting enzymatically active aspartic proteinase, and EP 574 347 describes Aspergillus hosts defective in a serine protease of the subtilisin-type.
Metalloproteases have been isolated from a number of eucaryotic sources. Neutral metalloproteases, i.e. metalloproteases having optimal activity at neutral pH, isolated from strains of *Aspergillus* also have been reported. Neutral metalloproteases have been classified into two groups, Npl and NplI [Sekine; *Agric. Biol. Chem.* 1972 36 207-216]. Recently the nucleotide sequence of a neutral metalloprotease II cDNA from *Aspergillus oryzae* have been disclosed [Tatsumi H, Murakami S, Tsuji R F, Ishida Y, Murakami K, Masaki A, Kawabe H, Arimura H, Nakano E and Motai H; *Mol. Gen. Genet.* 1991 228 97-103]. The nucleotide sequence of a neutral metalloprotease I cDNA from *Aspergillus oryzae* have never been disclosed.

Although metalloproteases have been reported, their role in relation to reducing the stability of the products obtained from these organisms have never been described.

**SUMMARY OF THE INVENTION**

According to the present invention it has now been found that metalloproteases may reduce significantly the stability of the product obtained by a cell.

Accordingly, the present invention provides a host cell useful for the expression of a heterologous protein product, which cell has been genetically modified in order to express significantly reduced levels of a metalloprotease, as compared to the parental cell.

In another aspect, the invention provides a method of producing a heterologous protein product in a host cell of the invention, which method comprises introducing into the host cell a nucleic acid sequence encoding the protein, cultivating the host cell in a suitable growth medium, and isolating the heterologous protein product.

By the method of the invention, the proteolytic action arising from metalloproteases have been significantly reduced, thereby improving the stability of the protein obtained by the method. Moreover, the protein obtained by the method
of the invention can be obtained as a precursor protein, i.e. a zymogen, a hybrid protein, a protein obtained as a pro sequence or pre-pro sequence, or in un-maturated form.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention is further illustrated by reference to the accompanying drawing, in which:

Fig. 1 shows a map of plasmid pSO2, cf. Example 2;
Fig. 2 shows the construction of Aspergillus oryzae strain HowB101, cf. Example 2;
Fig. 3 shows the construction of plasmid pJaL335, cf. Example 2;
Fig. 4 shows the construction of plasmid pJaL399, cf. Example 2;
Fig. 5 shows the construction of plasmid pJaL218, cf. Example 4; and
Fig. 6 shows a map of plasmid pToC56, cf. Example 5.

DETAILED DISCLOSURE OF THE INVENTION

Host Cells

The present invention provides a host cell useful for the expression of heterologous proteins, which cell, when compared to the parental cell, has been genetically modified in order to express significantly reduced levels of a metalloprotease.

The parental cell is the source of said host cell. It may be a wild-type cell. Alternatively, besides a decrease in metalloprotease level, it may be genetically altered in another respect.

In order to produce the desired protein, the host cell of the invention obviously must hold structural (i.e. regions comprising the coding nucleotide sequences) and regulatory (i.e. regions comprising nucleotide sequences necessary for e.g. transcription, translation and termination) genetic regions necessary for the
expression of the desired product. The nature of such structural and regulatory regions greatly depends on the product and the host cell in question. The genetic design of the host cell of the invention may be accomplished by the person skilled in the art, using standard recombinant DNA technology for the transformation or transfection of a host cell [vide e.g. Sambrook et al.; Molecular Cloning, Cold Spring Harbor, NY, 1989].

Preferably, the host cell is modified by methods known in the art for introduction of an appropriate cloning vehicle, i.e. a plasmid or a vector, comprising a DNA fragment encoding the desired product. The cloning vehicle may be introduced into the host cell either as an autonomously replicating plasmid or integrated into the chromosome. Preferably the cloning vehicle comprises one or more structural regions operably linked to one or more appropriate regulatory regions.

The structural regions are regions holding nucleotide sequences encoding the desired product. The regulatory regions include promoter regions comprising transcription and translation control sequences, terminator regions comprising stop signals, and polyadenylation regions. The promoter, i.e. a nucleotide sequence exhibiting a transcriptional activity in the host cell of choice, may be one derived from a gene encoding an extracellular or an intracellular protein, preferably an enzyme, such as an amylase, a glucoamylase, a protease, a lipase, a cellulase, a xylanase, a oxidoreductase, a pectinase, a cutinase, or a glycolytic enzyme. Examples of suitable promoters for transcription in a fungal host cell are promoters derived from the gene encoding Aspergillus oryzae TAKA amylase, Aspergillus niger neutral α-amylase, Aspergillus niger acid stable α-amylase, Aspergillus niger or Aspergillus awamspii glucoamylase (gluA), Aspergillus niger acetaimidase, Aspergillus oryzae alkaline protease, Aspergillus oryzae triose phosphatase isomerase, Rhizopus mehei aspartic proteinase, and Rhizopus mehei lipase. Preferred are the Aspergillus oryzae TAKA-amylase and Aspergillus awamsii gluA promoters.

The cloning vehicle may also comprise a selectable marker, e.g. a gene, the product of which complements a defect in the host cell, or one which confers antibiotic resistance, such as ampicillin, kanamycin, chloramphenicol or tetracycline resistance. Examples of Aspergillus selection markers include amds,
pyrG, argB, niaD and sc, a marker giving rise to hygromycin resistance. Preferred for use in an Aspergillus host cell are the amdS and pyrG markers of Aspergillus nidulans or Aspergillus oryzae. A frequently used mammalian marker is the dihydrofolate reductase (DHFR) gene. Furthermore, selection may be accomplished by co-transformation.

The procedures used to ligate the DNA construct of the invention, the promoter, terminator and other elements, respectively, and to insert them into suitable cloning vehicles containing the information necessary for replication, are well known to persons skilled in the art [vide e.g. Sambrook et al.; Molecular Cloning, Cold Spring Harbor, NY, 1989].

The host cell of the invention may be any host cell conventionally used for heterologous expression of proteins.

Preferably, the host cell of the invention is a yeast or a filamentous fungus capable of producing a desired protein. In particular, the yeast cell may be a strain of Saccharomyces, preferably Saccharomyces cerevisiae. In particular, the filamentous fungus may be a strain selected from the group consisting of Acremonium, Aspergillus, Candida, Cocciobolus, Endothia, Fusarium, Humicola, Neurospora, Rhizomucor, Rhizopus, Thermomyces, Trichoderma, Podospora, Pyricularia, or Penicillium.

In a preferred embodiment, the filamentous fungus is a strain selected from the group consisting of Aspergillus oryzae, Aspergillus niger, Aspergillus nidulans, Aspergillus awamori, Aspergillus phoenicis, Aspergillus japonicus, Aspergillus foetus, Fusarium graminearum, Fusarium oxysporum, Fusarium solani, Humicola grisea, Neurospora crassa, Penicillium chrysogenum, Rhizomucor miehei, Trichoderma reesei, or Trichoderma viride.

Products

The desired end product, i.e. the heterologous protein expressed by the host cell of the invention, may be any eubacterial or eucaryotic protein.

As defined herein, a "heterologous protein product" is a protein which is not native to the host cell, or a native protein in which modifications have been made to alter the native sequence, or a native protein whose expression is
quantitatively altered as a result of a manipulation of a native regulatory sequence
required for the expression of the native protein, such as a promoter, a ribosome
binding site, etc., or other manipulation of the host cell by recombinant DNA
techniques.
5 Owing to the absence of metalloprotease, the heterologous protein
expressed by the host cell may also be a precursor protein, i.e. a zymogen, a hybrid
protein, a protein obtained as a pro sequence or pre-pro sequence, or in un-
maturated form. In a preferred embodiment the product is an enzyme.

In a more specific embodiment, the product is an eucaryotic enzyme,
10 such as insulin, growth hormone, glucagon, somatostatin, interferon, PDGF, factor
VII, factor VIII, urokinase, EPO, chymosin, tissue plasminogen activator, or serum
albumin.

In another preferred embodiment, the product is an enzyme of fungal,
of yeast, or of bacterial origin.
15 Preferably the enzyme is a glycosidase enzyme, e.g. an amylase, in
particular an α-amylase (EC 3.2.1.1), a β-amylase (EC 3.2.1.2), a glucan 1,4-α-
glucosidase (EC 3.2.1.3), a cellulase (EC 3.2.1.4), an endo-1,3(4)-β-glucanase (EC
3.2.1.6), an endo-1,4-β-glucanase (EC 3.2.1.8), a polygalacturonase (EC 3.2.1.15),
an α-glucosidase (EC 3.2.1.20), a β-glucosidase (EC 3.2.1.21), an α-galactosidase
(3.2.1.22), a β-galactosidase (EC 3.2.1.23), a xylan-endogl-α,β-xylosidase (EC
3.2.1.32), an endo-1,3-β-glucanase (EC 3.2.1.39), an endo-1,3-α-glucanase (EC
3.2.1.59), an endo-1,2-β-glucanase (EC 3.2.1.71), an endo-1,6-β-glucanase (EC
3.2.1.75), a cellulose-1,4-β-cellobiosidase (EC 3.2.1.91, also known as
cellobiohydrolases).
20 In another preferred embodiment the enzyme is a lipolytic enzyme, in
particular a lipase, an esterase, a phospholipase, or a lyso-phospholipase.

In a third preferred embodiment the enzyme is a phytase, in particular
a 3-phytase (EC 3.1.3.8) or a 6-phytase (EC 3.1.3.26).

In a fourth preferred embodiment the enzyme is a proteolytic enzyme.

In a fifth preferred embodiment the enzyme is an oxidoreductase, such
30 as a peroxidase or a laccase, a pectinase, or a cutinase.
Preferred hybrid polypeptides are prochymosin and pro-trypsin-like proteases.

**Metalloproteases**

In the context of this invention a metalloprotease is a proteolytic enzyme containing a catalytic zinc metal center which participates in the hydrolysis of the peptide backbone. The active zinc center differentiates these proteases from calpains, whose activities are dependent upon the presence of calcium. Confirmation of a protease as a metalloprotease is loss of proteolytic activity accomplished by removal of the zinc center. The zinc center can be removed with 1,10-phenanthroline (1 mM). After titration with Zn\(^{2+}\) (0.1-100 μM), proteolytic activity is restored.

In a preferred embodiment, the metalloprotease contemplated in the context of this invention is a *Fusarium* metalloprotease, preferably a *Fusarium oxysporum* metalloprotease. In a most preferred embodiment, the metalloprotease is a *Fusarium oxysporum* p45 metalloprotease having the amino acid sequence presented as SEQ ID NO: 2, or a sequence homologous hereto.

In another preferred embodiment, the metalloprotease contemplated in the context of this invention is a neutral metalloprotease, which is a metalloprotease possessing optimal proteolytic activity in the neutral pH region, i.e. in the range of about pH 6-8, preferably the range of about pH 6.5-7.5, around pH 7.

More particularly, the metalloprotease contemplated in the context of this invention is a neutral *Aspergillus* metalloprotease of group Npl or Npl II.

In a preferred embodiment, the metalloprotease is an *Aspergillus oryzae* Neutral Metalloprotease I (Npl) encoded by a cDNA comprising the partial nucleotide sequence presented as SEQ ID NO: 4, or a sequence homologous hereto.

The degree of homology may be determined as the degree of identity between the two sequences indicating a derivation of the first sequence from the second. The homology may suitably be determined by means of computer programs, by methods known in the art, e.g. by comparing 50 bp continuous sequences. As defined herein, the protein encoded by a homologous cDNA sequence exhibits a degree of homology of at least 70% homology, preferably more
than 80% homology, more preferred more than 90% homology, most preferred more than 95% homology, with the sequence in question.

The gene encoding the metalloprotease may be identified by screening by hybridization for nucleic acid sequences coding for all of, or part of, the metalloprotease, e.g. by using synthetic oligonucleotide probes, that may be prepared on the basis of a cDNA sequence, e.g. the nucleotide sequences presented as SEQ ID NO: 1 and SEQ ID NO: 4, or on the basis of the amino acid sequence of the metalloprotease, in accordance with standard techniques [vide e.g. Sambrook et al.; Molecular Cloning, Cold Spring Harbor, NY, 1989].

10 Genetic Modifications

The host cell of the invention, genetically modified in order to express significantly reduced levels of a metalloprotease, may be modified using standard recombinant DNA technology, known to the person skilled in the art. The gene sequence responsible for the production of metalloprotease may be inactivated or eliminated entirely.

In a particular embodiment, the host cell of the invention is one genetically modified at the structural or regulatory regions encoding the metalloprotease. Known and useful techniques include, but are not limited to, specific or random mutagenesis, PCR generated mutagenesis, site specific DNA deletion, insertion and/or substitution, gene disruption or gene replacement techniques, antisense techniques, or a combination thereof.

Mutagenesis may be performed using a suitable physical or chemical mutagenizing agent. Examples of a physical or chemical mutagenizing agent suitable for the present purpose includes ultraviolet (UV) irradiation, hydroxylamine, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), O-methyl hydroxylamine, nitrous acid, ethyl methane sulphonate (EMS), sodium bisulfite, formic acid, and nucleotide analogues. When such agents are used, the mutagenesis is typically performed by incubating the cell to be mutagenized in the presence of the mutagenizing agent of choice under suitable conditions for the mutagenesis to take place, and selecting for mutated cells having a significantly reduced production of metalloprotease.
Modification may also be accomplished by introduction, substitution or removal of one or more nucleotides in the metalloprotease encoding sequence or a regulatory element required for the transcription or translation thereof. Nucleotides may, e.g., be inserted or removed so as to result in the introduction of a stop codon, the removal of the start codon or a change of the open reading frame. The modification or inactivation of the structural sequence or a regulatory element may be accomplished by site-directed mutagenesis or PCR generated mutagenesis in accordance with methods known in the art. Although in principle, the modification may be performed in vivo, i.e. directly on the cell carrying the metalloprotease gene, it is presently preferred to conduct the modification in vitro.

A convenient way to inactivate or reduce the metalloprotease production of a host cell of choice is based on the principles of gene interruption. This method involves the use of a DNA sequence corresponding to the endogenous gene or gene fragment which it is desired to destroy. Said DNA sequence is in vitro mutated to a defective gene and transformed into the host cell. By homologous recombination, the defective gene replaces the endogenous gene or gene fragment. It may be desirable that the defective gene or gene fragment encodes a marker which may be used for selection of transformants in which gene encoding the metalloprotease has been modified or destroyed.

Alternatively, the modification or inactivation of the DNA sequence may be performed by use of established anti-sense techniques using a nucleotide sequence complementary to the metalloprotease encoding sequence, e.g. the nucleotide sequences presented as SEQ ID NO: 1 and SEQ ID NO: 4.

Owing to genetic modification, the host cell of the invention expresses significantly reduced levels of metalloproteases. In a preferred embodiment the level of metalloprotease expressed by the host cell is reduced more than about 50%, preferably more than about 85%, more preferred more than about 90%, most preferred more than about 95%. In a most preferred embodiment, the product expressed by the host cell is essentially free of any metalloprotease activity.
Methods of Producing Proteins

In another aspect, the invention provides a method of producing proteins (i.e. polypeptides and/or proteins), which method comprises cultivating the host cell of the invention in a suitable growth medium, followed by recovery of the desired product.

By the method of the invention, the proteolytic action of metalloproteases have been significantly reduced, thereby improving the stability of the product obtained. Moreover, owing to the absence of metalloprotease, the heterologous protein expressed by the host cell may be obtained as a precursor protein, i.e. a zymogen, a hybrid protein, a protein obtained as a pro sequence or pre-pro sequence, or in unprocessed form.

The broth or medium used for culturing may be any conventional medium suitable for growing the host cell in question, and may be composed according to the principles of the prior art. The medium preferably contain carbon and nitrogen sources and other inorganic salts. Suitable media, e.g. minimal or complex media, are available from commercial suppliers, or may be prepared according to published receipts, e.g. the American Type Culture Collection (ATCC) Catalogue of strains.

After cultivation, the protein is recovered by conventional method for isolation and purification proteins from a culture broth. Well-known purification procedures include separating the cells from the medium by centrifugation or filtration, precipitating proteinaceous components of the medium by means of a salt such as ammonium sulphate, and chromatographic methods such as e.g. ion exchange chromatography, gel filtration chromatography, affinity chromatography, etc.

EXAMPLES

The invention is further illustrated with reference to the following examples which are not intended to be in any way limiting to the scope of the invention as claimed.
Materials and Methods

Strains


*Fusarium oxysporum* DSM 2672, deposited according to the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSM), Mascheroder Weg 1b, DE-3300 Braunschweig, Germany, on 6 June 1983.

*Escherichia coli* DH5α, Hanahan *D*, *J. Mol. Biol.* 1983 166 557.

Genes

Npl, which gene encodes Neutral Metalloprotease I.

NpII, which gene encodes Neutral Metalloprotease II.

pyrG: which gene encodes orotidine-5’-phosphate decarboxylase, an enzyme involved in the biosynthesis of uridine.

Plasmids

pUC118; Yanish-Perron *et al.*, 1985 *Gene* 33 103.

pJaL389; Construction of this plasmid from cosmid 3E8 is described in Example 1.

pSO2; Construction of this plasmid is described in Example 2.

pJers4; A subclone of pSO2.

pJaL335; Construction of this plasmid from pSO2 is described in Example 2.

pSO5; Construction of this plasmid from pSO2 is described in Example 2.

pJaL198; Construction of this plasmid from pJaL198 is described in Example 3.

pJaL218; Construction of this plasmid from pJaL218 is described in Example 4.
pToC90; A subclone of p3SR2.
pToC56; Construction of this plasmid is described in EP 238,023 B.
pToC65; Construction of this plasmid is described in EP 531 372 B.
pCR™II; Available from Invitrogen Corporation, San Diego, CA, USA.

EXAMPLE 1

Cloning of *Aspergillus oryzae* Neutral Metalloprotease I (Npl)

Construction of a Cosmid Library of *Aspergillus oryzae*

The library was essentially constructed according to the instruction from the supplier (Stratagene) of the "SuperCos1 Cosmid Vector Kit".

Genomic DNA of *Aspergillus oryzae* IFO 4177 was prepared from protoplasts made by standard procedures [cf. e.g. *Christensen et al.*, *Biotechnology* 1989 6 1419-1422]. After isolation of the protoplasts these were pelleted by centrifugation at 2500 rpm for 5 minutes in a Labofuge™ T (Heto), the pellet was suspended in 10 mM NaCl, 20 mM Tris-HCl (pH 8.0), 1 mM EDTA, 100 µg/ml Proteinase™ K and 0.5% SDS, as described in the manual from the SuperCos 1 Cosmid Vector Kit, as was the rest of the DNA preparations.

The size of the genomic DNA was analyzed by electrophoresis using the CHEF-gel apparatus from Biorad. A 1% agarose gel was run for 20 hours at 200 volt with a 10-50 second pulse. The gel was stained by ethidium bromide and photographed. The DNA was 50-100 kb in size. The DNA was partially restricted by Sau3A. The size of the restricted DNA was 20-50 kb determined the same way.

The CsCl gradient banded SuperCos1 vector was prepared according to the supplier’s manual, as was ligation and packaging. After titration of the library, all of the packaging mix from one ligation and packaging was transfected into the host cells XL1-Blue MR and plated on 50 µg/ml ampicillin LB plates. Approx. 3800 colonies were obtained. Cosmid preparation from 10 colonies showed that they all had inserts of expected size. The colonies were picked individually and inoculated in microtiter plate wells with 100 µl LB (100 µg/ml ampicillin) and incubated at 37°C over night. 100 µl of 50% glycerol was added to each well, and the whole library was
frozen at -80°C. A total of 3822 colonies were stored. This represents the *Aspergillus oryzae* genome approx. 4.4 times.

**Cloning *Fusarium oxysporum* p45 Metalloprotease Gene**

**Purification**

*Fusarium oxysporum* DSM 2672 broth is centrifuged at 9000 rpm for 10 minutes and the supernatant is filtered through a 0.45 μm filter. 200 ml of filtrate is concentrated down to 10 ml on an Amicon cell (PM 10 membrane) and Centriprep-0 (Amicon). 5 ml of concentrate is diluted to 100 ml and pH adjusted to 5 with acetic acid and run on a 1 ml Mono-S column in the following buffer: 0.1 M borate, 10 mM DMG, 2 mM calcium chloride, pH 5.2, in a gradient of 0 to 0.5 M sodium chloride over 70 minutes. After 10 minutes of wash in the above identified buffer at a flow rate of 1 ml/minute, 1.5 ml fractions are collected and concentrated on Centricon-10 (Amicon).

Gel filtration using Superose-12 (HR 10/30, Pharmacia) is performed in 0.1 M borate, 10 mM DMG, 2 mM CaCl₂, pH 6.5, flow rate 0.4 ml/minute. 0.4 ml fractions are collected. 200 μl samples are injected.

**Proteolytic Enzyme Assay**

Metalloprotease activity is measured as released trypsin activity from the pro-trypsin-like protease from the strain *Fusarium oxysporum* DSM 2672, after a 30-60 minutes pre-incubation at 25°C in 0.1 M TRIS, 2 mM CaCl₂, pH 7 (at lower pH, 100 mM borate, 10 mM DMG, 2 mM CaCl₂ is used). The trypptic activity is measured in microtiter plates, 100 μl samples are mixed with 100 μl of substrate (stock: 87 mg/ml L-BAPNA (Sigma) in DMSO, diluted 50-fold in buffer), and the absorption at 405 nm is measured using a Thermomax reader from Molecular Devices.

**SDS-PAGE and Electro Blotting onto PVDF**

SDS-PAGE (10-27%, Novex) is run according to the manufacturer’s instructions. Samples to be run are pre-incubated with PMSF before adding sample buffer. Electro blotting onto pro-blot membranes (Applied Biosystems) is performed
in 3 mM Na₂CO₃, 10 mM NaHCO₃, 20% MeOH, pH 9.9, at 30 V for 2 hours using the blotting module from Novex. The pro-blott is stained as described by Applied Biosystems.

IEF-overlay

Isoelectric focusing (IEF) is run on an Ampholine PAG-plate (Pharmacia), pH 3.5 to 9.5, and stained according to the manufacturer's instructions. The gel to be overlaid is first equilibrated for 15 minutes in 0.1 M TRIS, 2 mM CaCl₂, pH 8.1, and then overlaid with 10 ml 1% agarose, 0.1 M TRIS, 2 mM CaCl₂, pH 8.1, added 300 µl L-BAPNA (Sigma) stock and 500 µl pro-trypsin-like *Fusarium oxysporum* DSM 2672 protease (~ 0.25 mg/ml).

Amino Acid Analysis and Amino Acid Sequencing

Microwave facilitated vapor phase hydrolysis of lyophilized samples is performed using the MDS-2000 hydrolysis station (CEM). 6 N HCl containing 1% phenol (scavenger) is used for creating the vapor phase. Hydrolysis time is 20 minutes at 70 psi (~ 148°C). Hydrolysed samples are lyophilized and redissolved in 20 µl of 500 pmol/µl sarcosine and norvaline as internal standard. The analysis is done using the AminoQuant from Hewlett-Packard according to the manufacturer's instructions. 1 µl of sample is injected. Amino acid sequencing is performed using the 476A Protein Sequencer from Applied Biosystems according to the manufacturer's instructions. Premixed buffers are used for the online-HPLC.

Purification of p45 from *Fusarium oxysporum* Broth

The p45 metalloprotease is purified from concentrated and filtered fermentation broth by cation-exchange chromatography (Mono-S) followed by gel filtration on Superose 12. Fractions from Mono-S are selected by assaying for metalloprotease activity as released trypsin-like activity from pro-trypsin-like *Fusarium oxysporum* DSM 2672 protease.

Metalloprotease containing fractions from the Superose-12 column are identified by the same assay procedure as for the Mono-S fractions. The purified metalloprotease appears as a single band on SDS-PAGE at 45 kDa. Two isoforms
of the metalloprotease are observed in IEF (pH 3.5-9.5) at respectively pI 8.4 and 8.7.

Results from amino acid analysis indicate that this metalloprotease (p45) has the N-terminal amino acid sequence shown in the Sequence Listing as SEQ ID NO: 3.

Cloning of *Fusarium oxysporum* p45 Metalloprotease Gene and Characterization of Recombinant p45

A portion of the *Fusarium oxysporum* p45 metalloprotease gene is first cloned by PCR. One primer is designed using the N-terminal protein sequence (SEQ ID NO: 3), and a reverse primer is designed from an internal metalloprotease peptide sequence (residues 483-515 of SEQ ID NO: 1). PCR is performed using the DNA primers and genomic DNA isolated from *Fusarium oxysporum*. Genomic DNA is isolated as follows.

Approximately 15 g wet weight *Fusarium oxysporum* is grown in MY50 medium (50 g/l maltodextrin, 2 g/l MgSO₄, 10 g/l KH₂PO₄, 2 g/l citric acid, 10 g/l yeast extract, 2 g/l urea, 2 g/l K₂SO₄, 0.5 ml trace metal solution, adjusted to pH 6 with 5 N NaOH) at 30°C. Mycelia are suspended in 16 ml TE (10 mM TRIS, 1 mM EDTA, pH 8.0), split into two tubes, and approx. 12 g of 0.45-0.52 mm glass beads (Thomas Scientific) are added to each tube. The samples are alternately vortexed and iced for 30 second intervals until a noticeable viscosity breakdown occurs. The samples are alternately vortexed two additional 30 second intervals. 2.5 ml 20% SDS is added to each sample. The samples are mixed by inversion, incubated 10 minutes at room temperature, and mixed again. Samples are spun 8 minutes at 3.5 K at room temperature. Supernatants are combined in a 50 ml polypropylene tube. The sample is extracted with an equal volume of TE equilibrated with phenol:chloroform:isoamyl alcohol (25:24:1) (P/C/l extracted), then centrifuged 10 minutes at 10,000 rpm at 4°C. The supernatant is treated with 300 µl 10 mg/ml Proteinase K for 30 minutes at 25°C. The DNA is P/C/l extracted as described above, ethanol precipitated and dissolved in 5 ml TE. The sample is treated with 150 µl 10 30 mg/l RNAase A for 15 minutes at 65°C, then 15 minutes at 25°C. The sample is treated again with Proteinase K (100 µl 10 mg/ml for 1.5 hours at 25°C) and P/C/l
extracted twice and ethanol precipitated. The DNA is pooled onto a bent pasteur pipet and transferred to 5 ml 80% ethanol. The sample is spun 3 minutes at 10,000 rpm. The DNA pellet is dried briefly, then dissolved in 1 ml TE.

PCR is used to clone a portion of the *Fusarium oxysporum* p45 gene. 50-100 ng *Fusarium oxysporum* genomic DNA is mixed with approx. 100 pmoles each of the synthetic PCR primer DNAs in 1X Taq buffer (Boehringer Mannheim) and a concentration of 100 µl each of dGTP, dATP, dTTP and dCTP in a volume of 50 µl. Taq DNA polymerase (Boehringer Mannheim), 1-5 units, is added, and the PCR incubations are, 95°C for 5 minutes, then 35 cycles of [95°C for 30 seconds; 50°C for 1 minute; and 72°C for 1 minute].

The PCR reaction produces two DNA fragments of approx. 1.0 and 1.3 kb in length. These fragments are isolated by gel electrophoresis, purified, cloned into an *E. coli* replicating plasmid, and sequenced using standard methods known in the art of molecular biology. The 1.0 kb DNA fragment is found to contain *Fusarium oxysporum* p45 gene sequences by a comparison of the translations of the DNA with amino acid sequences obtained from direct protein sequencing. Therefore, this 1.0 kb PCR generated DNA fragment is used as a probe to clone the entire metalloprotease gene from a *Fusarium oxysporum* genomic DNA library.

A genomic library in lambda phage is prepared from the *Fusarium oxysporum* genomic DNA using methods such as those described by Sambrook *et al.* [Sambrook *et al*.; Molecular Cloning, Cold Spring Harbor, NY, 1989]. A total of 50 µg genomic DNA is digested in a volume of 200 µl containing 10 mM TRIS, pH 7.5, 50 mM NaCl, 7 mM MgCl₂, 7 mM 2-mercaptoethanol, and 4 units restriction enzyme Sau3A for one minute at 25°C. Partially digested DNA of molecular size 10-20 kb is isolated by agarose gel electrophoresis, followed by electroelution into dialysis membrane and concentration using an Elutip-D column (Schleicher and Schuell). One µg of lambda arms of phage of EMBL4, that had been cut with restriction enzyme BamH1 and treated with phosphatase (Clonetech), is ligated with 300-400 µg Sau3A cut genomic DNA in a volume of 25 µl under standard conditions [cf. Sambrook *et al*.; Molecular Cloning, Cold Spring Harbor, NY, 1989]. Lambda phage are prepared from this ligation mix using a commercially available kit (Gigapack Gold II, Stratagene), following the manufacturers instructions. The plating
of approx. 18,000 recombinant lambda phage, and the production of filter lifts (to N+ filters, Amersham) were performed using standard techniques [cf. Sambrook et al.; Molecular Cloning, Cold Spring Harbor, NY, 1989]. The filters are processed for hybridization with a Genious Kit for non-radioactive nucleic acids detection (Boehringer Mannheim) using the instructions provided by the manufacturer. The DNA used as p45 probe is the 1.0 kb PCR fragment obtained as described above. The probe is labelled by PCR incorporation of dioxigenin (DIG) using a DIG labelling kit and the instructions supplied by the manufacturer. Fifteen ng of the 1.0 kb p45 fragment is mixed in 1X Taq Buffer (Boehringer Mannheim) with 100 pmoles each N-terminal primer and internal reverse primer, and 1-5 units Taq polymerase (Boehringer Mannheim) in a total volume of 80 μl. Reaction conditions were 95°C for 3 minutes, then 35 cycles of [95°C for 30 seconds; 50°C for 1 minute; and 72°C for 1 minute], and 72°C for 5 minutes. The filter hybridizations using the DIG labelled probe and the wash conditions were performed using the instructions provided by the Genious Kit manufacturer.

Hybridizing phages are detected with an alkaline phosphatase-conjugated anti-dioxigenin antibody visualized with Lumiphos 530 as described by the manufacturer (Boehringer Mannheim). DNA preparations are made from the positive lambda clones using the Qiagen Lambda Midi Kit (QIAGEN, Inc.). DNA from one preparation is digested with restriction enzyme EcoR1 and a 6.3 kb fragment is subcloned into plasmid pUC118. DNA sequence analysis of portions of this subclone identified the entire coding region of the p45 gene, cf. SEQ ID NO: 1.

Cloning p45 Metalloprotease cDNA

Total RNA and poly-A RNA is prepared from Fusarium oxysporum according to the previous published protocols [Chirgwin et al., Biochemistry, 1988 18 5294-5299; Aviv and Leder, Proc. Natl. Acad. Sci., USA, 1972 69 1408-1412; Sambrook et al.; Molecular Cloning, Cold Spring Harbor, NY, 1989] with the following modifications.

Specifically, mycelia is ground in liquid nitrogen to a fine powder and then resuspended, with stirring, in a lysis buffer containing 4 M guanidinium thiocyanate, 0.5% Na-laurylsarcosine, 25 mM Na-citrate and 0.1 M 2-mercapto-
ethanol, pH 7.0, for 30 minutes at room temperature. Cell debris is removed by low speed (5000 rpm for 30 minutes) centrifugation. Typically, the poly-A RNA fraction is isolated using oligo (dT) cellulose obtained from Boehringer Mannheim.

The poly-A RNA is used to generate cDNA using the hairpin/RNaseH 5 method [Sambrook et al.; Molecular Cloning, Cold Spring Harbor, NY, 1989]. Specifically, 5 µg poly-A RNA in 5 µl water is heated at 70°C, then placed on ice. A total reaction mix of 50 µl is prepared containing the poly-A RNA, 50 mM TRIS, pH 8.3, 75 mM KCl, 3 mM MgCl₂, 10 mM DTT, 1 mM each dGTP, dATP, dTTP and dCTP, 40 units RNasin, 10 µg oligo (dT12-18) primer, and 1000 units SuperScript II RNase H- reverse transcriptase (Bethesda Research Laboratories). The mix is incubated at 45°C for one hour. Then 30 µl of 10 mM TRIS, pH 7.5, 1 mM EDTA, 40 µg glycogen carrier (Boehringer Mannheim), 0.2 volumes 10 M ammonium acetate, and 2.5 volumes ethanol were added to precipitate the nucleic acids. After centrifugation, the pellet is resuspended in 20 mM TRIS, pH 7.4, 90 mM KCl, 4.6 mM MgCl₂, 10 mM ammonium sulphate, 16 µM βNAD⁺, 100 µM each dGTP, dATP, dTTP and dCTP, 44 units E. coli DNA polymerase I, 6.25 units RNaseH, and 10.5 units DNA ligase. Second strand DNA synthesis is performed in this solution at 16°C for 3 hours. The DNA is concentrated by ethanol precipitation and the pellet is resuspended in 30 µl of 30 mM Na-acetate, pH 4.6, 300 mM NaCl, 1 mM ZnSO₄, 0.35 mM DTT, 2% glycerol, and 30 units Mung Bean nuclease (Bethesda Research Laboratories) at 30°C for 30 minutes. The DNA solution is neutralized with 70 µl 10 mM TRIS, pH 7.5, 1 mM EDTA, phenol extracted, and ethanol precipitated. The pellet is treated with 7.5 units T4 polymerase (Invitrogen) at 25°C for 15 minutes in 50 µl buffer (20 mM TRIS-acetate, pH 7.9, 10 mM Mg-acetate, 50 mM K-acetate, 1 mM DTT, 0.5 mM each dGTP, dATP, dTTP and dCTP). The reaction is stopped by addition of EDTA to 20 mM followed by phenol extraction and ethanol precipitation. The result of this procedure is double stranded cDNA with blunt ends suitable for attachment of DNA linkers and cloning into any vector.

The cDNA with EcoR1 linkers is size fractionated on an agarose gel to obtain cDNAs of molecular size 0.7 kb or greater. The cDNA is recovered from the gel by electroelution and purified by phenol extraction and ethanol precipitation. The size fractionated cDNA is used to construct a lambda cDNA library. The cDNA is
cloned into lambda ZIPLOX arms (Gibco BRL). Full length cDNA clones are identified using a 467 bp dioxigenin labeled fragment as probe (bp 336-803 of the genomic clone) with the techniques of plaque lifts and DNA hybridization as previously described. Full length cDNA is recovered in plasmid pZL1 as described by the manufacturer (strains and plasmid from Bibco BRL).

The full length cDNA is sequenced and compared with the sequence of the genomic DNA. The genomic DNA is 2052 bp in length and contains three introns. The predicted coding region of pre-pro p45 metalloprotease consists of a putative 18 amino acid signal sequence, a 226 amino acid pro-region, and a 388 amino acid mature region, as shown in SEQ ID NO: 1.

Preparation of *Fusarium oxysporum* p45 Metalloprotease Probe

A clone from the above cDNA library was selected and designated pDM115. Plasmid pDM115 contains a 1.76 kb fragment of *Fusarium oxysporum* cDNA, that encodes part of the p45 gene. This plasmid was digested with Sall and the fragments were separated on a 1% agarose gel. The 1.5 kb fragment was cut out and DNA eluted. This fragment was labelled with 32-P-dATP by random-primed labeling and used for either Southern or colony lift probing.

Screening *Aspergillus oryzae* Library with *Fusarium oxysporum* p45 Probe

The individually frozen colonies in the library were inoculated onto LB-20 plates (100μg/ml ampicillin) by using a multipin device with 6 times 8 pins fitting into half a microtiter dish. Plates were made containing colonies from all clones in the library. The plates were incubated at 37°C over night. Sterilized Whatman 540 filters cut to the size of a petri dish were placed upon the colonies which were incubated for two more hours at 37°C. The filters were transferred to LB plates containing 25 200μg/ml of chloramphenicol and the plates were incubated over night at 37°C. The next day the filters were washed twice in 0.5 M NaOH for 5 minutes, then twice in 0.5 M Tris-HCl (pH 7.4) for 5 minutes and then twice in 2 x SSC for 5 minutes. The filters were wet with ethanol and air dried.

The filters were hybridized with the 1.5 kb 32P labelled DNA fragment 30 from pDM115 containing the protease gene from *Fusarium oxysporum*. The
hybridization was carried out for 16 hours at 65°C in 10 x Denhart, 5 x SSC, 0.02 M EDTA, 1% SDS, 0.15 mg/ml polyA, and 0.05 mg/ml yeast tRNA. After hybridization the filters were washed in 2 x SSC, 0.1% SDS at 65°C twice and placed on X-ray films. Three colonies showed hybridization to the probe, namely 3E8, 3C1 and 2A5, the names refer to their position in the library.

Characterization of the Cosmid Clones

By restriction analysis it was established that two of the three cosmid clones (3E8 and 3C1) contained inserts which were derived from the same region of the Aspergillus oryzae genome.

3 µg of cosmid DNA was digested with EcoRI and fractionated by agarose gel electrofocuse. The DNA was transferred to Immobilan-N membrane filters and hybridized with the 1.5 kb radiolabelled probe from pDM115. The probe hybridized to a 4 kb EcoRI fragment in both cosmid clones. The 4.0 kb EcoRI fragment was chosen for further analysis.

Cloning of Npl into the Plasmid pToC65 and its Sequence

Plasmid pToC65 was digested with Sacl and treated with bacterial alkaline phosphatase to remove the 5’-phosphate groups according to the manufacturers instructions. Afterwards it was phenol extracted and precipitated.

The 5.5 kb Sacl fragment from cosmid clone 3E8 containing the Aspergillus oryzae Npl gene was isolated by gel electrophoresis and purified.

The two fragments were mixed together and ligated. After transformations of E. coli, the colonies carrying the correct plasmid were identified by restriction enzyme digestion of mini-plasmid preparations. This plasmid was called pJaL389.

Comparison of DNA sequence analysis of portions of this subclone to other known Npl gene sequences was used to identify that the subclone contains the coding region of the Aspergillus oryzae Npl gene.
EXAMPLE 2

Genomic Disruption of *Aspergillus oryzae* Neutral Metalloprotease Npl

In order to generate strains of *Aspergillus oryzae* that are specifically
deficient in the production of Npl, a gene replacement strategy as described by
5 *Miller et al.; Mol. Cell. Biol.* 1985 5 1714-1721, was employed. Below, these
experiments are described in more details.

Cloning of the *Aspergillus oryzae* pyrG gene

The *Aspergillus oryzae* pyrG gene was cloned by cross hybridization
with the *Aspergillus niger* pyrG gene [W. van Hartingsveldt et al.; *Mol. Gen. Genet*
10 1987 206 71-75]. A lambda library of partial SauIIA digested *Aspergillus oryzae* IFO
4177 DNA was probed at low stringency with a 1 kb DNA fragment from the
*Aspergillus niger* pyrG gene. DNA from a positive clone was subcloned into a
pUC118 vector. The resultant plasmid, pSO2, was shown to contain the pyrG gene
by complementation of an *Aspergillus niger* pyrG - mutant, cf. Fig. 1.

Construction of an *Aspergillus oryzae* pyrG Minus Strain

A pyrG deletion plasmid, pSO5, containing about 1 kb of pyrG flanking
sequences on each end, was constructed from the plasmid pSO2. The strain
*Aspergillus oryzae* IFO 4177 was transformed with this construct and transformants
were selected by resistance to 5-fluoro-orotic acid, a phenotype characteristic of
pyrG mutants.

One transformant, HowB101, was shown by Southern analysis to have
the expected deletion at the pyrG locus. Being a pyrG mutant, HowB101 requires
uridine for growth. HowB101 can be transformed with the wt pyrG gene by selection
for ability to grow without uridine.

The steps involved in the construction of HowB101 are illustrated in Fig.
2.
Construction of Plasmid pJaL335

In order to amplify a 431 bp fragment located 479 nucleotides upstream from the 5' end of the *Aspergillus oryzae* pyrG gene, the two following oligonucleotides were made:

5 Primer A: GGAGAAGATCTCTTGTCATCTCTCGATCTC; SEQ ID NO: 5; and
6 Primer B: GGAGGAGAATTCAAGCTTCTCTCATACACAGTGTIGAAAGC; SEQ ID NO:

The underlined part corresponds to the *Aspergillus oryzae* pyrG gene sequence.

The 5' ends of the primers were for facilitating cloning (Primer A contains a BglIII restriction endonuclease site, and primer B contains a EcoRI and a HindIII restriction endonuclease site).

Plasmid pSO2 was used as template in the PCR reaction. Amplification was performed in 100 µl volumes containing 2.5 units Taq-polymerase, 100 ng of pSO2, 50 mM KCl, 10 mM Tris-HCl pH 8.0, 1.5 mM MgCl2, 250 nM of each dNTP, and 10 pmol of each of the two primers described above.

Amplification was carried out in a Perkin-Elmer Cetus DNA Termal 480, and consisted of one cycle of 3 minutes at 94°C, followed by 25 cycles of 1 minutes at 94°C, 30 seconds at 55°C, and 1 minutes at 72°C. The PCR reaction produced one DNA fragment of 430 bp in length. This fragment was digested with BglIII and EcoRI, and isolated by gel electrophoresis. It was purified and cloned into the corresponding site in plasmid pSO2. The resulting plasmid was called pJaL335. The construction of pJaL335 is illustrated in Fig. 3.

Construction of Disruption Plasmid pJaL399

Plasmid pJaL389 was digested with BalI, and treated with Klenow polymerase to make the ends blunt. The 7.1 kb fragment was isolated by gel electrophoresis, and purified. This DNA fragment was then treated with bacterial alkaline phosphatase to remove the 5' phosphate groups according to the manufacturer’s instructions and phenol extracted and precipitated.

Plasmid pJaL335 was digested with HindIII, and treated with Klenow polymerase to make the ends blunt. The 3.5 kb fragment encoding the *Aspergillus oryzae* pyrG gene was isolated by gel electrophoresis and purified.
The two fragments were mixed together and ligated. After transformations of *E. coli*, the colonies carrying the correct plasmids were identified by restriction enzyme digestion of mini-plasmid preparations. The construction of pJaL399 is illustrated in Fig. 4.

pJaL399 holds a pToC65 vector containing a fragment which carries the Npl gene flanked by Sacl sites, and where the central 1.1 kb BalI fragment has been replaced by an 3.5 kb DNA fragment encoding the *Aspergillus oryzae* pyrG gene.

**Transformation of Aspergillus oryzae**

15 µg of plasmid pJaL399 are digested to completion by Sacl. The completeness of the digest is checked by running an aliquot on a gel and the remainder of the DNA is phenol extracted, precipitated and resuspended in 10 8.25 µl of sterile water.

The transformation of *Aspergillus oryzae* HowB101 host strain is preformed by the protoplast method [Christensen et al.; Biotechnology 1988 6 1419-1422]. Typically, *Aspergillus oryzae* mycelia is grown in a rich nutrient broth. The mycelia is separated from the broth by filtration. Novozyme® (available from Novo Nordisk A/S, Denmark) is added to the mycelia in an osmotically stabilizing buffer such as 1.2 M MgSO₄ buffered to pH 5.0 with sodium phosphate. The suspension is incubated for 60 minutes at 37°C with agitation. The protoplasts are filtered through mira-cloth to remove mycelial debris. The protoplasts are harvested and washed twice with STC (1.2 M sorbitol, 10 mM CaCl₂, 10 mM Tris-HCl pH 7.5). Finally, the protoplasts are resuspended in 200-1000 µl STC.

For transformation 5 µg DNA is added to 100 µl protoplast suspension. 200 µl PEG solution (60% PEG 4000, 10 mM CaCl₂, 10 mM Tris-HCl pH 7.5) was added, and the mixture is incubated for 20 minutes at room temperature. The protoplasts are harvested and washed twice with 1.2 M sorbitol. The protoplasts are finally resuspended in 200 µl 1.2 M sorbitol, plated on selective plates (minimal medium + 10 g/l Bacto-Agar (Difco), and incubated at 37°C. After 3-4 days of growth at 37°C, stable transformants will appear as vigorously growing and sporulating colonies.
Identification of Gene Disruption

From the stable colonies, individual spores are streaked on fresh minimal plates. Single colonies are selected and restreaked to give pure cultures. These are used to inoculate 10 ml of liquid YPM medium (1% yeast extract, 1% peptone, 2% maltose). After 18 hours at 30°C and shaking at 180 rpm, the mycelia is harvested on filter paper. Mycelia is then transferred to an 2 ml eppendorf tube and freeze dried.

After freeze drying DNA is prepared from the individual mycelia by grinding the mycelia to a fine powder with a pestle in the tube. This powder is resuspended in 0.5 ml of 50 mM EDTA pH 8.0, 0.2% SDS, 1 µl DEP, by vortexing. After incubation at 65°C for 20 minutes, 0.1 ml 5 M KAc pH 6.5, is added and the solution is mixed and incubated on ice for 5 minutes. The cell debris is separated from the DNA solution by centrifugation at 20,000 rpm for 5 minutes. 0.4 ml supernatant is precipitated with 0.3 ml isopropanol and centrifugated at 20,000 rpm for 10 minutes. The DNA pellet is redissolved in 100 µl of sterile TE buffer containing 0.1 mg/ml RNAaseA.

3 µg of each DNA is digested with Ball, fractionated by agarose gel electropherase, transferred to Immobilan-N membrane filters. The filters were hybridized with the 5.5 kb ³²P labelled DNA Sacl fragment from pJaL389 containing the Npl protease gene. Strains which carry a disruption of the Npl gene are recognized by lacking the 1.1 kb Ball hybridizing fragment as well as having altered mobility of the other two flanking fragments.

EXAMPLE 3

Cloning of Aspergillus oryzae Neutral Metalloprotease II (NplII)

Construction of pJaL198

From the published cDNA nucleotide sequence encoding Aspergillus oryzae NplII [Tatsumi et al.; Mol. Gen. Genet. 1991 228 97-103], two oligonucleotides were designed so that the encoding part of the NplII gene was amplified in a PCR reaction.
A primer (CTAGGATCCAAAGGCATTATCGTGCTACTCCTC; SEQ ID NO: 7) was constructed so that the 3' end of the nucleotide sequence corresponds to the N-terminal part of the NpII gene (underlined), and the 5'-end is for facilitating cloning (contains a BamHI restriction endonuclease site).

A primer (CTACTCGAGTTAGCACTTGGCTCGATAGC; SEQ ID NO: 8) was constructed so that the 3' end of the nucleotide sequence corresponds to the C-terminal part of the NpII gene (underlined), and the 5'-end is for facilitating cloning (contains a Xhol restriction endonuclease site).

Genomic DNA from Aspergillus oryzae IFO 4177 was used as template in the PCR reaction. Amplification reaction was performed in 100 μl volumes containing 2.5 units Taq-polymerase, 100 ng of Aspergillus oryzae genomic DNA, 50 mM KCl, 10 mM Tris-HCl pH 8.0, 1.5 mM MgCl2, 250 nM of each dNTP, and 100 pM of each of the two primers described above.

Amplification was carried out in a Perkin-Elmer Cetus DNA Thermal 480, and consisted of one cycle of 3 minutes at 94°C, followed by 25 cycles of 1 minutes at 94°C, 30 seconds at 55°C, and 1 minutes at 72°C. The PCR reaction produces one DNA fragment of approx. 1.1 kb in length. This fragment was isolated by gel electrophoresis, purified, cloned into the vector pCR™II (Invitrogen Corporation), and sequenced using standard methods known in the art of molecular biology. The resulting plasmid was called pJaL198.

EXAMPLE 4
Genomic Disruption of NpII
Construction of JaL121

In order to generate strains of Aspergillus oryzae that were specifically deficient in the production of NpII, a gene replacement strategy as described by Miller et al.; Mol. Cell. Biol. 1985 5 1714-1721, was employed.

Cloning Aspergillus oryzae pyrG Gene

1987 206 71-75]. A lambda library of partial Sau3AI digested *Aspergillus oryzae* IFO 4177 DNA was probed at low stringency with a 1 kb DNA fragment from the *Aspergillus niger* pyrG gene. DNA from a positive clone was subcloned into a pUC118 vector. The resultant plasmid, pSO2, was shown to contain the pyrG gene by complementation of an *Aspergillus niger* pyrG - mutant, cf. Fig. 1.

**Construction of an *Aspergillus oryzae* pyrG Minus Strain**

A pyrG deletion plasmid, pSO5, containing about 1 kb of pyrG flanking sequences on each end, was constructed from the plasmid pSO2. The strain *Aspergillus oryzae* IFO 4177 was transformed with this construct, and transformants were selected by resistance to 5-fluoro-uracylic acid, a phenotype characteristic of pyrG mutants. One transformant, HowB101, was shown by Southern analysis to have the expected deletion at the pyrG locus. Being a pyrG mutant, HowB101 requires uridine for growth. HowB101 can be transformed with the wt pyrG gene by selection for ability to grow without uridine.

The steps involved in the construction of HowB101 are illustrated in Fig. 2.

**Construction of Disruption Plasmid pJaL218**

Plasmid pJaL198 is digested with BstEI and treated with Klenow polymerase to make the ends blunt. The 4.9 kb fragment was isolated by gel electrophoresis and purified. This DNA fragment was then treated with bacterial alkaline phosphatase to remove the 5' phosphate groups, according to the manufacturers instructions, phenol extracted and precipitated.

Plasmid pJers4 was digested with HindIII and treated with Klenow polymerase to make the ends blunt. The 1.8 kb fragment encoding the *Aspergillus oryzae* pyrG gene was isolated by gel electrophoresis and purified.

The two fragments were mixed and ligated. After transformations of *E. coli* DH5α, the colonies carrying the correct plasmids are identified by restriction enzyme digestion of mini-plasmid preparations. The construction of pJaL218 is illustrated in Fig. 5.
pJaL218 consists of the pCR™II vector containing a fragment which carries the NpII gene flanked by EcoRI sites, in which the central BstEI fragment has been replaced by a 1.8 kb DNA fragment encoding the *Aspergillus oryzae* pyrG gene.

5 **Transformation *Aspergillus oryzae***

15 µg of plasmid pJaL218 is digested to completion by EcoRI. The completeness of the digest was checked by running an aliquot on a gel. The remainder of the DNA was phenol extracted, precipitated and resuspended in 10 µl of sterile water.

The transformation of *Aspergillus oryzae* HowB101 host strain was performed by the protoplast method [Christensen et al.; Biotechnology 1988 6 1419-1422]. Typically, *Aspergillus oryzae* mycelia was grown in a rich nutrient broth. The mycelia was separated from the broth by filtration. Novozyme™ (available from Novo Nordisk A/S, Denmark) was added to the mycelia in an osmotically stabilizing buffer, 1.2 M MgSO₄, sodium phosphate buffer pH 5.0. The suspension was incubated for 60 minutes at 37°C with agitation. The protoplast was filtered through Miracloth to remove mycelial debris. The protoplast was harvested and washed twice with STC (1.2 M sorbitol, 10 mM CaCl₂, 10 mM Tris-HCl pH 7.5). The protoplast was finally resuspended in 200-1000 µl STC.

For transformation, 5 µg DNA was added to 100 µl protoplast suspension. 200 µl PEG solution (60% PEG 4000, 10 mM CaCl₂, 10 mM Tris-HCl pH 7.5) was added, and the mixture is incubated for 20 minutes at ambient temperature. The protoplast was harvested and washed twice with 1.2 M sorbitol. The protoplast was finally resuspended 200 µl 1.2 M sorbitol, plated on selective plates (minimal medium + 10 g/l Bacto-Agar (Difco), and incubated at 37°C.

After 3-4 days of growth at 37°C, stable transformants appear as vigorously growing and sporulating colonies.

**Identification of Gene Disruptions**

From stable colonies, individual spores are streaked on fresh minimal plates. Single colonies are selected and restreaked to give pure cultures.
Thirty-three transformants were screened to see if the transformed DNA fragment had integrated by a double overcross into the corresponding gene on the chromosome by PCR. PCR reaction and genomic DNA from the transformants was performed as described above.

The primers used were CCCTTTTTTCAAACCG (SEQ ID NO: 9), which is located 5' from the encoding region of the NplI gene, and pyrG-5' (GGGTGAGCCACTGCCTC; SEQ ID NO: 10), which is specific for the pyrG gene. One transformant yielded the expected PCR product on 1.1 kb.

From Southern blots, where genomic DNA from the transformant and 10 from Aspergillus oryzae was digested with EcoRI, fractionated by agarose gel electrophoresis, transferred to Immobilon-N membrane filters, and probed with the 1.1 kb EcoRI fragment from pJaL198 containing the NplI gene, it was found that the wild-type band on 3.8 kb was shifted to a 10 kb band in the transformant. This proves that the transformed DNA was integrated into the NplI gene in multiple copies. The strain was designated JaL121.

EXAMPLE 5
Production of Chymosin in JaL121

Aspergillus oryzae strain JaL121 was transformed with the plasmid pToC56 (cf. Fig. 6), which is a fungal expression plasmid for the mammalian enzyme chymosin, by co-transformation with pToC90. The construction of plasmid pToC56 is described in EP 98 993 A.

Transformants were selected for growth on minimal medium containing 10 mM acetamide, and screened for the presence of pToC56 by the ability to produce chymosin. A transformant was grown in shake flasks for 4 days at 30°C in a medium containing maltodextrin, soybean meal and peptone. A transformant of pToC56 in Aspergillus oryzae IFO 4177 was grown together with the JaL121 transformant.

Each day, fermentation broth samples were collected and applied to SDS-Page and Western blotting. The blotting membrane was incubated with
chymosin specific rabbit antibody, followed by goat rabbit antibody coupled to peroxidase.

Staining of the membrane showed that on the first and second day of fermentation, the supernatants from transformants of *Aspergillus oryzae* IFO 4177 contained small amounts of chymosin, or degradation products thereof. Later on no chymotrypsin was detected. In contrast, transformants of JaL121 contained at least ten times of full size chymosin. The amount of chymosin in the supernatants increased for the first two-three days and then remained constant.
SEQUENCE LISTINGS

INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 2052 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
   (A) ORGANISM: Fusarium oxysporum
   (B) STRAIN: DSM 2672
   (C) INDIVIDUAL ISOLATE: p45

(ix) FEATURE:
   (A) NAME/KEY: mat_peptide
   (B) LOCATION: 785..2049

(ix) FEATURE:
   (A) NAME/KEY: sig_peptide
   (B) LOCATION: 55..784

(ix) FEATURE:
   (A) NAME/KEY: intron
   (B) LOCATION: 364..415

(ix) FEATURE:
   (A) NAME/KEY: intron
   (B) LOCATION: 802..854

(ix) FEATURE:
   (A) NAME/KEY: intron
   (B) LOCATION: 1821..1868

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

ATGCCTTTCT CGACTCTCT CCTCTCTAC GGCCTATCCA GCCTCGCTGG TGCCTATCCC  60
AGCAGAAAGGG CTCTTAATCC TTCACCGCTG AGCAAGCGTG GCCTCGACCT GGAAGCTTTT 120
AAGCTTCTC CCAAGCGGCA CTAGTTCCT CAGGACGAGG TTCTCTGACTA TGGCCTGGCC 180
AAGGTCGTCA CCAAGCGGCG TAATACACC GAGACTGCCA AGGACTTTGG TAAAGTCCACG 240
TTCCCAGGT CACTTTTCCG TATGGTCACG GATCACTATG TTGTTAGCAA CAGGAAATGCC 300
CATGTTAATCT TTAAGCGACG TGTCACCGGT ATGATATCG ACAATGCTGA TTTAAACGTC 360
AACGTTGGGTAT TTCTCCAAGAC TTGGGAGGAT TGGAATGTG CTGACATGGGA TACAGATTGG 420
CGCTGACGCG CAGGCTTCTT CTCAGCGAAA CAGCTTCTAC GAGGGCAAGA TTCCCGGTCC 480
TCTTACCAAG CGTGACGAGAA AAGACCGCGT CGAGCCTTCTC AAGGACACCG TTGATGTCTT 540
TTCTCTCCCC GTTGGAGGCTG ACAAGCGGCAA GGCTGAGAAG AAGAGCAAAG ACCACTACAC 600
CTCTAAGGCT ATCCAGGCTA CGCTCAGCAA GCCGGAGGCAT AAGCTGACCT ACTCTGTTGA 660
5 TGAGAACCAAG GAGCTCAAGC TCACATGGAG ATTTGAGACT GATATTGTTG ACAACTGCGT 720
GTTGACTTAT GTCAATGCTG CCAAGAATCA GAGGTTGTTG GTGTTGTTTG ACTACGTCAA 780
TGAGGCCACA TACAAAGGCT ATGCAGCTTT TCCATAAAATG GAGATTTTG AAAAAATTGGA 840
CCGTTGTATT ATAGTCTTGG GGGTGCTAAT GATCCCTCCA AGGGATCTGG CCTCACCTGT 900
GAGAAACCCCT GGAATCTCGG AGCGCTCCCG TTCACCTGGG TCAGGACGGG CTCAAAACAC 960
10 TACACCAACA CCCGCGGCAA ATAGGAAATT GCACAGTTGA ATCCTTCAGG GGGCTCCAG 1020
TATCTGAACA ATTACCGTCTG TTAGATGCCTG TCACGTGAAT TCGAGTATGA TTACTCCACC 1080
AGCACCACAC ACAACCAAGC TACAGGCGAG CATGGCATTC CTCACGTTTT CTACACAGCC 1140
AAAAGAATCC ACGACCTCTC ATCCTTCCTT GGTTTACCGG AACAGGGCTGG TAATCTCCAG 1200
ACCAACAAACA ATGGCACAGG TGGTGTAAGA AAGATATTTG TTATCTCCAAG GCCTCAAGGAC 1260
15 GGAAGCGGCA CCAACACACG CAACCTCGCT ACACCCCGCTG ACGGTACGCC CGGGCGGCTG 1320
CAGATGTATC TCTGGACATA CAGCACACCC CAGCGTGACCT GCAGTTTCTG AGCTGGCGTT 1380
GTTATCCACG AGTACACTCA CGTCTTCTCC ACCAGTCTCA CAGGTTGCCG TGCCAACTTCG 1440
GGTGTCTTCG CCAGCTGGATG ATCCCGTGCC ATGGGTGAGG GCTGGGTGGA CTTCATGGCT 1500
ACTGCCATTG ACATCCACATCG CAGGGTAGAC ACAAGGCTCAT GGGTGACTGG 1560
20 GTGTACACCA AGCGAGCTGGG TATCCCGAGG TATCCCTTACA GCACAGCCTC TACCACATAC 1620
CCTTACACTT ACAAGAGGTGT TACAGTGCTC AGTGGAGTCC ATGGTATTTG TACTTTACTG 1680
GCTACTGTTC TGATGGAAGCT TATGTGGGAC CTCACTGCAAG AGCATGGGGAA GAATGATCGC 1740
GATGAGGCCA AATTCAACCA CGGCGTCTCT ACGATGGGCA AATATCTTGG TAGAGGTTCA 1800
GTAGTGGATG GCATGTGCTG GTAAGTGTGC CTTGGATTTG GTAGGAGTTC TTATCTAACG 1860
25 TTAAATAGGC AACCTTGCAAA CCAACCATGT GCACCGGGCC GAGACCCCAT CTACGACGCC 1920
GACCGCCTC TTACCAAGGG AGCTAAGAC TGCGAGATCT GGAAGGCTGG TGCCAAACCGT 1980
GGTCTTGGAAAT CTGGTGCCCA ATGATATGCT TCCAGCCGTA CTGAGAGCTT TGCTCTTCCT 2040
TCTGGATGGT AA 2052
INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 388 amino acids
   (B) TYPE: amino acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:
   (A) ORGANISM: Fusarium oxysporum
   (B) STRAIN: DSM 2672
   (C) INDIVIDUAL ISOLATE: p45

(xii) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

```
   Ala Thr Tyr Lys Val Tyr Pro Trp Gly Val Asn Asp Pro Ser Lys Gly 1 5 10 15
   Ser Arg Ser Thr Val Glu Asn Pro Trp Asn Leu Ala Ala Ser Glu Phe 20 25 30
   Thr Trp Leu Ser Asp Gly Ser Asn Tyr Thr Thr Thr Arg Gly Asn 35 40 45
   Asn Gly Ile Ala Gln Val Asn Pro Ser Gly Gly Ser Thr Tyr Leu Asn 50 55 60
   Asn Tyr Arg Pro Asp Ser Pro Ser Leu Lys Phe Glu Tyr Asp Tyr Ser 65 70 75 80
   Thr Ser Thr Thr Thr Pro Thr Thr Tyr Arg Asp Ala Ser Ile Ala Gln 85 90 95
   Leu Phe Tyr Thr Ala Asn Lys Tyr His Asp Leu Tyr Leu Tyr Leu Gly 100 105 110
   Phe Thr Glu Gln Ala Gly Asn Phe Gln Thr Asn Asn Gly Gln Gly 115 120 125
   Gly Val Gly Asn Asp Met Val Ile Leu Asn Ala Gln Asp Gly Ser Gly 130 135 140
   Thr Asn Asn Ala Asn Phe Ala Thr Pro Ala Asp Gly Gln Pro Gly Arg 145 150 155 160
   Met Arg Met Tyr Leu Trp Thr Tyr Ser Thr Pro Gln Arg Asp Cys Ser 165 170 175
   Phe Asp Ala Gly Val Val Ile His Glu Tyr Thr His Gly Leu Ser Asn 180 185 190
```
Arg Leu Thr Gly Gly Pro Ala Asn Ser Gly Cys Leu Pro Gly Gly Glu
   195  200  205
Ser Gly Gly Met Gly Glu Gly Trp Gly Asp Phe Met Ala Thr Ala Ile
   210  215  220
His Ile Gln Ser Lys Asp Thr Arg Ala Ser Asn Lys Val Met Gly Asp
   225  230  235  240
Trp Val Tyr Asn Ala Ala Gly Ile Arg Ala Tyr Pro Tyr Ser Thr
   245  250  255
Ser Leu Thr Thr Asp Pro Tyr Thr Tyr Lys Ser Val Asn Ser Leu Ser
   260  265  270
Gly Val His Ala Ile Gly Thr Tyr Trp Ala Thr Val Leu Tyr Glu Val
   275  280  285
Met Trp Asn Leu Ile Asp Lys His Gly Lys Asn Asp Ala Asp Glu Pro
   290  295  300
Lys Phe Asn Asn Gly Val Pro Thr Asp Gly Lys Tyr Leu Ala Met Lys
   305  310  315  320
Leu Val Val Asp Gly Met Ser Leu Gln Pro Cys Asn Pro Asn Met Val
   325  330  335
Gln Ala Arg Asp Ala Ile Ile Asp Ala Asp Thr Ala Leu Thr Lys Gly
   340  345  350
Ala Asn Lys Cys Glu Ile Trp Lys Gly Phe Ala Lys Arg Gly Leu Gly
   355  360  365
Thr Gly Ala Lys Tyr Ser Ala Ser Ser Arg Thr Glu Ser Phe Ala Leu
   370  375  380
Pro Ser Gly Cys
   385

INFORMATION FOR SEQ ID NO: 3:
(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 14 amino acids
   (B) TYPE: amino acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(v) FRAGMENT TYPE: N-terminal
(vi) ORIGINAL SOURCE:
   (A) ORGANISM: Fusarium oxysporum
(B) STRAIN: DSM 2672
(C) INDIVIDUAL ISOLATE: p45
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Ala Thr Tyr Lys Val Tyr Pro Trp Gly Val Asn Asp Pro Ser

INFORMATION FOR SEQ ID NO: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 747 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Aspergillus oryzae
(B) STRAIN: IFO 4177
(C) INDIVIDUAL ISOLATE: MpI
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

GGTGAGGGGA TGAATGACCC GACGGAGGAC CCTCGCACCAG TCATCAGCGA TCCATGGGAT
TGTCGCGCAT CTGATTCGAC CGGATCGT ACGGAGGAC CGACACTACCCT ACGGATGCT GACAGAACTAC
GGGAACCAGG GACCGGAG TGGGACTCTTT AGCTTTATT GAGGTCAACG GACGGAAAA CACAACCCCA
GAGTCCTATA TGATGCGTC TATCCTCAG CTCTTCTACA CTGGAAACCG GACGGGATCC CTGAGTAATT TCCAGTACGA TAACAATGGG
AAAGGAGGTTG CTGAAACGAC ATCGTGATC CTCAATCTCTG AGAAGCT GGGCGTAATA TGGGACAAAT
AACGGCAACT TCGTACGCC CCGGATGGA CAGCCCCGCC GCATGCGGAT GTACATATGG
ACCAGTGCCC AGCTTTACG TGAGGGCTCC TCTTGGGCTG GTATGGGAT TCACGAGTAT
ACTCAGGCCC GTATGTACCC TTTAAGACAC CAAGAAGG CAGTCTGAAC TAACACCCACG
GCAACAGGTC TCTAACCACCC GCGCTTGGG ACCCGCCTAC TCTCGTGTGTT TGAATGCTCT
TGAAATCCGCGC GAAATGCTGAGG TGGTGGGAG GACTCTCAGT GCCACCGTAT TCTCGGCTCA
GTGAGGAGATCGGCGAT CTGACTCTCG ATCCCTT
INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

GGAGGAAGATCTCTCTGGTACTCTTCGATCTC

INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

GGAGGAGAATTCAAGCTTCTTCTACATCAGTTTGAAAAGC

INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

CTAGGATCCA AGGCATTTAT GCGTGTCACT ACTCTC

INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA

(x) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

CTACTCGAGT TAGCACTTGA GCTCGATAGC

INFORMATION FOR SEQ ID NO: 9:
(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 17 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(x) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

CCCTTCTTTC CAAACCG

INFORMATION FOR SEQ ID NO: 10:
(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 17 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(x) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

GGGTGAGCCA CTGCCTC
CLAIMS

1. A host cell useful for the expression of a heterologous protein product, which cell has been genetically modified in order to express significantly reduced levels of a metalloprotease, as compared to a parental cell.

2. The host cell according to claim 1, which is a yeast cell.

3. The host cell according to claim 2, which is a strain of *Saccharomyces*, preferably *Saccharomyces cerevisiae*.

4. The host cell according to claim 1, which is a filamentous fungus.

5. The host cell according to claim 4, which is a strain selected from the group consisting of *Acremonium*, *Aspergillus*, *Candida*, *Cochliobolus*, *Endothia*, *Fusarium*, *Humicola*, *Neurospora*, *Rhizomucor*, *Rhizopus*, *Thermomyces*, *Trichoderma*, *Podospora*, *Pyricularia*, and *Penicillium*.

6. The host cell according to claim 5, which is a strain selected from the group consisting of *Aspergillus oryzae*, *Aspergillus niger*, *Aspergillus nidulans*, *Aspergillus awamori*, *Aspergillus phoenicus*, *Aspergillus japonicus*, *Aspergillus foetus*, *Fusarium graminearum*, *Fusarium oxysporum*, *Fusarium solani*, *Humicola grisea*, *Neurospora crassa*, *Penicillium chrysogenum*, *Rhizomucor meihei*, *Trichoderma reesei*, and *Trichoderma viride*.

7. The host cell according to any of claims 1-6, in which the metalloprotease is a *Fusarium* metalloprotease.

8. The host cell according to claim 7, in which the metalloprotease is a *Fusarium oxysporum* metalloprotease.
9. The host cell according to claim 8, in which the metalloprotease is a *Fusarium oxysporum* p45 metalloprotease having the amino acid sequence presented as SEQ ID NO: 2, or a sequence homologous hereto.

10. The host cell according to any of claims 1-6, in which the metalloprotease is a neutral metalloprotease, having optimal proteolytic activity in the range of about pH 6-8.

11. The host cell according to claim 10, in which the metalloprotease is a neutral *Aspergillus* metalloprotease of group Npl or NplII.

12. The host cell according to claim 11, in which the metalloprotease is an *Aspergillus oryzae* Neutral Metalloprotease I (Npl) encoded by a cDNA sequence comprising the partial nucleotide sequence presented as SEQ ID NO: 4, or a sequence homologous hereto.

13. The host cell according to any of claims 1-12, which has been genetically modified at the structural or regulatory regions encoding the metalloprotease.

14. The host cell according to claim 13, which has been genetically modified by specific or random mutagenesis, PCR generated mutagenesis, site specific DNA deletion, insertion and/or substitution, gene disruption or gene replacement techniques, anti-sense techniques, or a combination thereof.

15. The host cell according to any of claims 1-14, in which cell the level of expressed metalloprotease is reduced more than about 50%, preferably more than about 85%, more preferred more than about 90%, most preferred more than about 95%.

16. The host cell according to any of claims 1-14, which cell is essentially free of any metalloprotease activity.
17. A method of producing a heterologous protein product in the host cell of claim 1, which method comprises,
   (a) introducing into said host cell a nucleic acid sequence encoding said protein product;
   (b) cultivating in a suitable growth medium, the host cell of step (a); and
   (c) isolating said heterologous protein product.

18. The method according to claim 17, in which the host cell is a yeast cell.

19. The method according to claim 18, in which the host cell is a strain of Saccharomyces, preferably Saccharomyces cerevisiae.

20. The method according to claim 17, in which the host cell is a filamentous fungus.

21. The method according to claim 20, in which the host cell is a strain selected from the group consisting of Acremonium, Aspergillus, Candida, Coclciobolus, Endothia, Fusarium, Humicola, Neurospora, Rhizomucor, Rhizopus, Thermomyces, Trichoderma, Podospora, Pyricularia, and Penicillium.

22. The method according to claim 21, in which the host cell is a strain selected from the group consisting of Aspergillus oryzae, Aspergillus niger, Aspergillus nidulans, Aspergillus awamori, Aspergillus phoenicis, Aspergillus japonicus, Aspergillus foetus, Fusarium graminearum, Fusarium oxysporum, Fusarium solani, Humicola grisea, Neurospora crassa, Penicillium chrysogenum, Rhizomucor miehei, Trichoderma reesei, and Trichoderma viride.

23. The method according to any of claims 17-22, in which the metalloprotease is a Fusarium metalloprotease.
24. The method according to claim 23, in which the metalloprotease is a *Fusarium oxysporum* metalloprotease.

25. The method according to claim 24, in which the metalloprotease is a *Fusarium oxysporum* p45 metalloprotease having the amino acid sequence presented as SEQ ID NO: 2, or a sequence homologous hereto.

26. The method according to any of claims 17-22, in which the metalloprotease is a neutral metalloprotease, having optimal proteolytic activity in the range pH 6 - 8.

27. The method according to claim 26, in which the metalloprotease is a neutral *Aspergillus* metalloprotease of group Npl or NplII.

28. The method according to claim 27, in which the metalloprotease is an *Aspergillus oryzae* Neutral Metalloprotease I (Npl) encoded by a cDNA sequence comprising the partial nucleotide sequence presented as SEQ ID NO: 4, or a sequence homologous hereto.

29. The method according to any of claims 17-28, in which the host cell has been genetically modified at the structural or regulatory regions encoding the metalloprotease.

30. The method according to claim 29, in which the host cell has been genetically modified by specific or random mutagenesis, PCR generated mutagenesis, site specific DNA deletion, insertion and/or substitution, gene disruption or gene replacement techniques, anti-sense techniques, or a combination thereof.

31. The method according to any of claims 17-30, in which the level of metalloprotease expressed by the host cell is reduced more than 50%, preferably more than 85%, more preferred more than 90%, most preferred more than 95%.
32. The method according to any of claims 17-30, in which the product expressed by the host cell is essentially free of any metalloprotease activity.

33. The method according to any of claims 17-32, in which the protein product is an eucaryotic enzyme, such as insulin, growth hormone, glucagon, somatostatin, interferon, PDGF, factor VII, factor VIII, urokinase, EPO, chymosin, tissue plasminogen activator, or serum albumin.

34. The method according to any of claims 17-32, in which the protein product is a protein of fungal origin.

35. The method according to claim 34, in which the protein product is a fungal enzyme, in particular an amylolytic enzyme, such as an α-amylase, a β-amylase, a glucoamylase, a β-galactosidase, a cellulytic enzyme, a lipolytic enzyme, a xylanolytic enzyme, a proteolytic enzyme, an oxidoreductase, such as a peroxidase or a laccase, a pectinase, or a cutinase.

36. The method according to any of claims 17-32, in which the protein product is a bacterial protein.

37. The method according to claim 36, in which the protein product is a bacterial enzyme, in particular an amylolytic enzyme, such as an α-amylase, a β-amylase, a glucoamylase, a β-galactosidase, a cellulytic enzyme, a lipolytic enzyme, a xylanolytic enzyme, a proteolytic enzyme, an oxidoreductase, such as a peroxidase or a laccase, a pectinase, or a cutinase.

38. The method according to any of claims 17-37, in which the protein product is a precursor protein, i.e. a zymogen, a hybrid protein, a protein obtained as a pro sequence or pre-pro sequence, or in unmaturated form.
FIG. 1
FIG. 2

SUBSTITUTE SHEET (RULE 26)
FIG. 3

SUBSTITUTE SHEET (RULE 26)
FIG. 4

SUBSTITUTE SHEET (RULE 26)
FIG. 5
SUBSTITUTE SHEET (RULE 26)
**INTERNATIONAL SEARCH REPORT**

**INTERNATIONAL application No.**
PCT/DK 96/00111

<table>
<thead>
<tr>
<th>A. CLASSIFICATION OF SUBJECT MATTER</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPC6: C12N 1/19, C12N 15/81, C12P 21/02 // C12N 9/58</td>
</tr>
<tr>
<td>According to International Patent Classification (IPC) or to both national classification and IPC</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B. FIELDS SEARCHED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minimum documentation searched (classification system followed by classification symbols)</td>
</tr>
<tr>
<td>IPC6: C12N</td>
</tr>
<tr>
<td>Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched</td>
</tr>
<tr>
<td>SE, DK, FI, NO classes as above</td>
</tr>
<tr>
<td>Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)</td>
</tr>
<tr>
<td>MEDLINE, BIOSIS, DBA, CA, WPI, EPOQUE, PAJ, US PATFULL, PATENT CITATION INDEX, SCISEARCH</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>C. DOCUMENTS CONSIDERED TO BE RELEVANT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Category*</td>
</tr>
<tr>
<td>------------</td>
</tr>
<tr>
<td>X</td>
</tr>
<tr>
<td>X</td>
</tr>
<tr>
<td>X</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C. See patent family annex.

- Special categories of cited documents:
  - "A" document defining the general state of the art which is not considered to be of particular relevance
  - "E" earlier document but published on or after the international filing date
  - "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  - "O" document referred to in an oral disclosure, use, exhibition or other means
  - "P" document published prior to the international filing date but later than the priority date claimed
  - "S" document of particular relevance; the invention could not be considered novel or cannot be considered to involve an inventive step when the document is taken alone
  - "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
  - "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
  - "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
  - "Z" document member of the same patent family

**Date of the actual completion of the international search**
11 June 1996

**Date of mailing of the international search report**
03 - 07 - 1996

<table>
<thead>
<tr>
<th>Name and mailing address of the ISA/Swedish Patent Office</th>
</tr>
</thead>
<tbody>
<tr>
<td>Box 5055, S-102 42 STOCKHOLM</td>
</tr>
<tr>
<td>Facsimile No. +46 8 666 02 86</td>
</tr>
</tbody>
</table>

Authorized officer

Patrick Andersson
Telephone No. +46 8 782 25 00

Form PCT/ISA/210 (second sheet) (July 1992)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 9300925 A1 (AMGEN INC.), 21 January 1993 (21.01.93), claims 22,24</td>
<td>1,17</td>
</tr>
<tr>
<td>A</td>
<td>--</td>
<td>2-16,18-38</td>
</tr>
<tr>
<td>D,A</td>
<td>WO 9000192 A1 (GENENCOR, INC.), 11 January 1990 (11.01.90)</td>
<td>1-38</td>
</tr>
</tbody>
</table>

Form PCT/ISA/210 (continuation of second sheet) (July 1992)
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>WO-A1- 9217595</td>
<td>15/10/92</td>
<td>AU-B- 661844</td>
<td>10/08/95</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU-A- 1750592</td>
<td>02/11/92</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU-A- 3660095</td>
<td>11/01/96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA-A- 2105064</td>
<td>02/10/92</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP-T- 6506117</td>
<td>14/07/94</td>
</tr>
<tr>
<td>EP-A2- 0341215</td>
<td>08/11/89</td>
<td>SE-T3- 0341215</td>
<td>15/07/95</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AT-T- 124086</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU-B,-B- 614121</td>
<td>22/08/91</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU-A- 3382889</td>
<td>09/11/89</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE-D,-T- 68923123</td>
<td>30/11/95</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES-T- 2072918</td>
<td>01/08/95</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL-A- 90170</td>
<td>31/12/95</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP-A- 2104279</td>
<td>17/04/90</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP-B- 8024565</td>
<td>13/03/96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT-B- 90436</td>
<td>30/11/94</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP-A- 2002385</td>
<td>08/01/90</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US-A- 5179003</td>
<td>12/01/93</td>
</tr>
<tr>
<td>WO-A1- 9300925</td>
<td>21/01/93</td>
<td>AU-B- 6555312</td>
<td>15/12/94</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU-A- 2307592</td>
<td>11/02/93</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA-A- 2090463</td>
<td>02/01/93</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP-A,-A,-A- 0546156</td>
<td>16/06/93</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP-T- 6501396</td>
<td>17/02/94</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ-A- 243356</td>
<td>27/04/94</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US-A- 5516685</td>
<td>14/05/96</td>
</tr>
<tr>
<td>WO-A1- 9000192</td>
<td>11/01/90</td>
<td>AT-T- 1177203</td>
<td>15/02/95</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA-A- 1333777</td>
<td>03/01/95</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE-D,-T- 68920882</td>
<td>17/08/95</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP-A,-A,-B- 0429490</td>
<td>05/06/91</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SE-T3- 0429490</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>HK-A- 110395</td>
<td>14/07/95</td>
</tr>
</tbody>
</table>